What stimulant substances does Ascend treat?
Ascend treats all forms of stimulant use disorder as classified in the DSM-5:
- Methamphetamine: A potent, highly addictive synthetic stimulant that causes massive dopamine release (approximately 1,250 units compared to 100 from normal pleasurable activities). Methamphetamine use has surged nationally, with 2.5 million Americans reporting use in the past year (2022 NSDUH).
- Amphetamines: Including illicit amphetamine and diverted prescription amphetamines (Adderall, Dexedrine). Prescription stimulant misuse is increasingly common among young adults.
- Prescription stimulants: Methylphenidate (Ritalin, Concerta) and amphetamine-based ADHD medications taken at doses or frequencies beyond prescription parameters, or obtained without a prescription.
Methamphetamine use has increased 43% between 2015 and 2022. In 2022, approximately 32,537 overdose deaths involved psychostimulants — predominantly methamphetamine — making it the fourth leading cause of drug overdose death in the United States.
Why is there no medication for stimulant addiction?
Despite extensive research, no pharmacological agent has demonstrated consistent efficacy for stimulant use disorder in large-scale clinical trials. The primary reason is the complexity of stimulant pharmacology — these substances affect multiple neurotransmitter systems (dopamine, norepinephrine, serotonin) in ways that are difficult to counteract with a single medication.
Several agents are under investigation:
- Mirtazapine: Antidepressant showing preliminary efficacy for methamphetamine use reduction
- Bupropion + naltrexone: Combination showing some promise in clinical trials for methamphetamine use disorder
- Lisdexamfetamine: Under study as agonist-replacement therapy, similar to methadone for opioid use disorder
- Injectable naltrexone: Being studied for methamphetamine use disorder with mixed results
Until a pharmacological breakthrough occurs, behavioral therapy remains the primary evidence-based treatment. Contingency management and cognitive behavioral therapy have the strongest empirical support for stimulant use disorders.
Questions About Why is there no?
Call our 24/7 admissions line or verify your insurance online.
What behavioral therapies does Ascend use for stimulant addiction?
Ascend uses a structured behavioral therapy approach built on the modalities with the strongest evidence base for stimulant use disorders:
- Contingency Management (CM): The most rigorously studied intervention for stimulant use disorder. The VA healthcare system's nationwide rollout of CM demonstrated significant reductions in stimulant use. Participants receive tangible reinforcement for verified abstinence (negative drug screens), creating a competing reward that counteracts the drug's reinforcement.
- Cognitive Behavioral Therapy (CBT): Structured therapy addressing thought patterns, triggers, and behaviors that maintain stimulant use. Includes functional analysis of use patterns, coping skills development, and cognitive restructuring.
- Motivational Interviewing (MI): Particularly important for stimulant users, who may have ambivalence about treatment or minimize consequences. MI strengthens intrinsic motivation and commitment to change.
- The Matrix Model: A structured 16-week outpatient program developed specifically for stimulant use disorders. Combines CBT, family education, 12-step facilitation, and relapse prevention in a manualized format with NIDA-demonstrated efficacy.
Group therapy, family systems work, and holistic modalities (exercise programming, yoga, mindfulness) complement these primary interventions. Regular physical exercise has demonstrated particular benefit for methamphetamine recovery by supporting dopamine system recovery.
“Stimulant addiction is uniquely challenging because the brain's reward system takes over a year to substantially recover. Clients need to understand this timeline. Our role is to provide the structure, therapy, and support that bridges the gap between early abstinence and neurological healing.”
What is the neuroscience of stimulant addiction recovery?
Chronic methamphetamine use causes measurable changes in brain structure and function, many of which are reversible with sustained abstinence.
Neuroimaging studies show that methamphetamine significantly damages the dopamine system, reducing dopamine transporter (DAT) availability and D2 receptor density. This produces the anhedonia (inability to feel pleasure), cognitive impairment, and depression commonly seen in early recovery. The good news: PET imaging studies demonstrate that dopamine transporter levels recover substantially after 12-17 months of abstinence.
Methamphetamine also causes neurotoxicity to serotonergic neurons, white matter degradation, and reduced gray matter volume in the prefrontal cortex. Cognitive deficits in attention, memory, and executive function typically improve over 6-12 months of abstinence, though some impairments may persist longer.
This neuroscience underscores the importance of long-term treatment engagement. The first 90 days are critical, but full neurological recovery takes 12-18 months. Ascend's continuum of care — from PHP through outpatient and telehealth — supports clients throughout this extended recovery timeline.
